期刊全稱 | Adjuvant Therapy of Primary Breast Cancer | 影響因子2023 | Hans-J?rg Senn,Aron Goldhirsch,Bruno Osterwalder | 視頻video | http://file.papertrans.cn/145/144982/144982.mp4 | 學(xué)科分類 | Recent Results in Cancer Research | 圖書封面 |  | 影響因子 | The ultimate "consumer" of the data presented at conferences on the primary treatment of operable breast cancer is the patient, and when, as in this disease, the benefits of therapy are relatively mod- est, the availability and interpretation of the data from trials be- comes an issue of primary importance. The effects of present treat- ment are in fact such that more patients relapse despite therapy than are estimated to benefit from it. It is, therefore, extremely dif- ficult for the physician to recommend unequivocally one particular adjuvant treatment modality for the vast population of women with breast cancer. The interpretation of results from clinical research-oriented pro- grams is constantly applied, however, in the treatment of breast cancer patients outside of clinical trials. From presented or publish- ed data, many physicians extrapolate indications for the use of a given treatment regimen for their patients, perceiving it as the "best available therapy. " It is essential that the "best available therapy" be selected individually for each patient. However, considering the modest effect of treatment upon outcome, it is imperative that those who provide the data - those | Pindex | Conference proceedings 1989 |
The information of publication is updating
|
|